[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre of Postgraduate Medical Education\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":227},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,80,107,127,149,174,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644857","intraoperative-lidocaine-or-dexmedetomidine-for-postoperative-pain-modulation-after-urethral-reconstruction-100644857",false,"NCT07676942","Intraoperative Lidocaine or Dexmedetomidine for Postoperative Pain Modulation After Urethral Reconstruction.","Effects of Intravenous Lidocaine and Dexmedetomidine Infusions on Postoperative Pain and the Development of Chronic Pain Following Urethral Reconstruction Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial.","Inclusion Criteria:\n\n* ASA status less or equal 3\n* Scheduled for reconstructive surgery of urethra\n* Able to understand information provided and to sign informed consent for participation in the study\n\nExclusion Criteria:\n\n* known allergy to one of the investigated medications\n* current chronic pain\n* known chronic use of opioids, gabapentinoids and antidepressants","MALE","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The development of chronic postoperative pain (CPP) following surgery is influenced by several factors, among which the intensity of acute postoperative pain in the immediate perioperative period and mechanisms related to nerve fiber injury play a crucial role. Previous studies have demonstrated that factors such as the severity of early postoperative pain, patient age, and the extent of surgical intervention may increase the risk of transition from acute to chronic pain. In recent years, growing attention has been directed toward anesthetic techniques and adjuvant analgesics (co-analgesics) administered during surgery, which may potentially reduce the incidence of CPP.\n\nThe aim of this study is to evaluate the effects of intraoperative intravenous infusions of dexmedetomidine or lidocaine during urethral reconstructive surgery on postoperative pain intensity, patient-reported quality of recovery, and the incidence and characteristics of chronic postoperative pain, including its neuropathic component. In particular, the study will investigate whether administration of these agents reduces pain intensity during the first 48 hours after surgery-which, according to existing evidence, may correlate with the risk of CPP development-and whether intraoperative infusion of lidocaine or dexmedetomidine translates into reduced pain severity and a lower risk of neuropathic pain at long-term follow-up (3, 6, and 12 months after surgery).\n\nAn important aspect of this project is that both investigational drugs-lidocaine and dexmedetomidine-have an established role in routine anesthesiology practice, and their safety profiles are well characterized and extensively documented in the medical literature. Intravenous lidocaine infusion has been used for many years as part of multimodal perioperative analgesia; numerous randomized controlled trials and meta-analyses have confirmed its efficacy in reducing postoperative pain intensity and opioid requirements, with a low risk of adverse effects when administered at therapeutic doses. Dexmedetomidine has been routinely used for years both in intensive care units and as a component of general anesthesia across a wide range of surgical procedures. Its analgesic, anxiolytic, and opioid-sparing effects have been supported by a substantial body of clinical evidence, and the doses used in the present protocol are consistent with established clinical practice.",[26],"Urethral Stricture",[28,29,30,31,32,33],"urethral reconstruction","buccal membrane graft","postoperative pain","neuropathic pain","lidocaine","dexmedetomidine","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2028-07",{"name":44,"class":45},"Centre of Postgraduate Medical Education","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100620490","phase-4-haemodynamic-effects-and-complications-of-continuous-versus-single-shot-spinal-anaesthesia-for-hip-fracture-surgery-100620490","NCT07358299","Haemodynamic Effects and Complications of Continuous Versus Single-shot Spinal Anaesthesia for HIP Fracture Surgery","A Comparison of Haemodynamic Effects, as Assessed by Cardiac Output Monitoring, and Complications of Continuous Versus Single-Shot Spinal Anaesthesia for Hip-Fracture Surgery in Patients Over 50 Years of Age","CHIPS","Inclusion Criteria:\n\n* Age \\> 50 years, regardless of gender\n* Diagnosis of a proximal femur fracture\n* Orthopedic qualification for open reduction and internal fixation of the fracture\n* Informed consent for the surgical procedure\n* Informed consent for regional anesthesia, i.e., a central neuraxial block (spinal anesthesia)\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Age \\\u003C 50 years, regardless of gender\n* Refusal to consent to surgical treatment\n* Refusal to consent to regional anesthesia\n* Refusal to consent to participate in the study\n* Inability to provide informed consent\n* Allergy to local anesthetic agents\n* Severe congenital or acquired coagulation disorders\n* Failure to meet the recommended time interval between the last dose of an anticoagulant and central neuraxial blockade, according to the 2022 European Journal of Anaesthesiology (EJA) guidelines\n* Infection at the block site or a systemic infection (i.e., sepsis, septic shock)\n* Patients with multiple organ dysfunction syndrome requiring hospitalization in the Intensive Care Unit for stabilization of vital functions\n* Clinical signs of increased intracranial pressure or suspicion of an intracranial mass on imaging studies\n* Other contraindications to spinal anesthesia as judged by the qualifying physician","ALL","50 Years",{"count":58,"type":20},216,[60],"PHASE4","This research project aims to identify a safer method of spinal anaesthesia for elderly patients undergoing surgical stabilisation of proximal femoral fractures.\n\nThe study's primary objective is to compare two spinal anaesthesia techniques: the continuous method (investigational), which allows titration of local anaesthetic doses through a catheter placed in the subarachnoid space, and the conventional single-shot bolus injection.\n\nThe main hypothesis is that the continuous catheter technique reduces the incidence of intraoperative hypotension and related complications, such as delirium, acute kidney injury, and cardiovascular events.\n\nBeyond haemodynamic stability-assessed through advanced continuous monitoring of cardiac output and vascular resistance-the study will evaluate early and late complications, as well as quality of life up to 24 months post-surgery.\n\nThe project is a prospective, randomised, multicentre clinical trial including at least 216 patients over 50 years of age, randomly assigned to one of the two groups.\n\nProximal femoral fractures are a major and growing global health issue, particularly among geriatric patients with multiple comorbidities. The conventional single-shot spinal anaesthesia, though widely used, carries a high risk of hypotension, potentially leading to delirium, acute kidney injury, stroke, and cardiac events. These complications worsen prognosis, decrease quality of life, and increase mortality.\n\nMost existing studies are over two decades old, based on small cohorts and outdated anaesthetic protocols, and lack long-term follow-up data (\\>30 days) on neurological outcomes, functional recovery, quality of life, and mortality. Moreover, no modern trials have provided direct, comprehensive comparisons between single-shot and continuous spinal anaesthesia.\n\nThis project therefore seeks to fill this critical evidence gap through a robust randomised clinical trial. Using precise, continuous measurements of arterial pressure, vascular resistance, and cardiac output, alongside long-term assessments of neurological outcomes, quality of life, and survival, it aims to determine whether continuous spinal anaesthesia offers superior safety and should become the new standard of care for this vulnerable population.",[63,64],"Anesthesia, Spinal","Hip Fractures",[66,67,68,69,70],"Continuous spinal anaesthesia","Late side effects of spinal anaesthesia","Haemodynamic stability","Follow-up care after proximal femoral fractures","Quality of life after proximal femoral fractures","2026-01-21",{"date":73,"type":38},"2026-01-23",{"date":75,"type":20},"2026-01-15",{"date":77,"type":20},"2029-11-01",{"name":44,"class":45},2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":55,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100552362","cardioneuroablation-fragmented-atrial-potentials-intracardiac-echocardiography-and-computed-tomography-100552362","NCT06472102","Cardioneuroablation: Fragmented Atrial Potentials, Intracardiac Echocardiography and Computed Tomography","Value of fRagmented Atrial electrOgrams, Computed Tomography and Intracardiac Echocardiography for Identification of optiMal Sites for Radio-frequency Delivery During cArdioneuroablation for Asystolic Reflex syNcope","Roman5","Inclusion Criteria:\n\n* severe, recurrent symptoms due to reflex syncope with ECG documented asystole \\>3 seconds, especially if associated with injury, or recurrent presyncope with persistent reflex bradycardia\n* history of ineffective prior non-pharmacological treatment and positive baseline atropine test (sinus rate acceleration \\> 30% and no AV block following 2 mg of intravenous atropine) -\n* informed written consent obtained\n\nExclusion Criteria:\n\n* contraindications to perform cardioneuroablation\n* contraindications to perform computed tomography with intravenous contrast injection\n* lack of informed written consent obtained","14 Years",{"count":90,"type":20},100,[23],"Cardioneuroablation (CNA) is a new method for the treatment of asystolic reflex syncope, however, optimal methods for identification of presumed sites of ganglionated plexi (GP), which are the target for CNA and are located in the epicardial fat, have not yet been established. This study will compare the accuracy of three methods used for identification of these areas: intracardiac recordings of fractionated atrial electrograms, intracardiac echocardiography and computed tomography. The study group will consist of 100 patients undergoing CNA in our institution. The procedure will be performed in a standard manner with the use of extracardiac vagal stimulation as the intraprocedural end-point. Correlation between the three methods used for localisation of optimal sites for CNA as well as their predictive value for achieving effective CNA will be computed.",[94],"Syncope, Vasovagal",[96,97],"cardioneuroablation","syncope","RECRUITING","2025-09-23",{"date":101,"type":38},"2025-09-26",{"date":103,"type":38},"2024-05-20",{"date":105,"type":20},"2025-12-31",{"name":44,"class":45},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100549917","cardioneuroablation-for-reflex-syncope-and-exercise-capacity-100549917","NCT06440291","Cardioneuroablation for Reflex Syncope and Exercise Capacity","Effects of caRdioneurOablation on Exercise perforMance in Patients With Reflex Asystolic syNcope: The Roman 3 Study","Roman3","Inclusion Criteria:\n\n* severe, recurrent symptoms due to reflex syncope or recurrent presyncope due to slow heart rate\n* ECG documented asystole \\>3 seconds\n* ineffective prior non-pharmacological treatment\n* positive baseline atropine test (sinus rate acceleration \\> 30% and no atrio-ventricular block following 2 mg of intravenous atropine)\n* signed written informed consent\n\nExclusion Criteria:\n\n* serious comorbidities precluding general anaesthesia and cardioneuroablation\n* non-functional sinus arrest or atrio-ventricular block (negative atropine test)\n* lack of consent to participate in the study",true,{"count":90,"type":20},[23],"Cardioneuroablation (CNA) is a new promising method to treat reflex syncope which is due to vagally-induced functional sinus arrest or atrio-ventricular block (AVB). Although the procedure is effective in \\> 80% of patients, there are potential adverse effects associated with the lack of vagal protection. One of them is increased sinus rate and possible worsening of exercise capacity. However, it is not known how often this happens. Moreover, the most accurate tool to asses exercise capacity - cardiopulmonary exercise testing (CPET), has not yet been used in this group of patients. Therefore, the aim of the study is to assess one-year effects of CNA-induced total vagal denervation on cardiorespiratory fitness in patients undergoing CNA due to reflex asystolic syncope.\n\nThe study group consists of patients undergoing CNA in our institution. All patients give informed written consent to undergo CNA and to participate in the study (Ethics Committee approval # 22\u002F2024). CNA is performed according to standard protocol used in our institution. A symptom-limited cardiopulmonary exercise (CPET) is performed twice, at baseline (1-2 days before CNA) and after one year of follow-up. Standard CPET parameters are measured. Quality of life is measured using a dedicated questionnaire. Also, a control group of healthy volunteers will undergo CPET to answer the question whether subjects with reflex syncope differ in exercise capacity from healthy people.",[94],[97],{"date":101,"type":38},{"date":123,"type":38},"2023-05-02",{"date":125,"type":20},"2025-12-01",{"name":44,"class":45},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":55,"minAge":88,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":148,"locationsCount":46},"100551288","cardioneuroablation-and-ventricular-proarrhythmia-100551288","NCT06458140","Cardioneuroablation and Ventricular Proarrhythmia","Acute electRophysiOlogical Changes of Ventricular Myocardium Following cArdioneuroablatioN for Asystolic Reflex Syncope","Roman4","Inclusion Criteria:\n\n* severe, recurrent symptoms due to reflex syncope with ECG documented asystole \\>3 seconds\n* history of ineffective prior non-pharmacological treatment\n* positive baseline atropine test (sinus rate acceleration \\> 30% and no atrio-ventricular block following 2 mg of intravenous atropine)\n* informed written consent to participate in the study\n\nExclusion Criteria:\n\n* Lack of consent to participate in the study\n* Contraindications to perform right ventricular stimulation",{"count":136,"type":20},50,[23],"Cardioneuroablation (CNA) is a promising tool to treat patients with asystolic reflex syncope. CNA acts through complete or near complete abolition of vagal nerve chronotropic and dromotropic effects on the heart, resulting in sinus node acceleration and improved atrio-ventricular conduction, which in turn prevents vagally-mediated reflex asystole. However, lack of parasympathetic protection may potentially be proarrhythmic, especially on the ventricular level. Whether this is a real threat is not known. Therefore, the aim of our study is to assess acute effects of CNA-induced total vagal denervation, measured by extracardiac vagal stimulation, on ECG and electrophysiological parameters as well as vulnerability to ventricular arrhythmias. The study group will consist of 50 consecutive patients undergoing CNA in our institution. Cardioneuroablation will be performed in standard manner. The following parameters will be assessed at baseline and after CNA (directly after CNA, after atropine injected after CNA and after isoproterenol bolus injected at the very end of the procedure): QTc interval, QT dispersion, right ventricular action potential duration, right ventricular effective refractory period and susceptibility to complex ventricular arrhythmias using programmed ventricular stimulation.",[94],[96,141,142],"reflex syncope","ventricular arrhythmia","2025-05-10",{"date":145,"type":38},"2025-05-14",{"date":103,"type":38},{"date":105,"type":20},{"name":44,"class":45},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":158,"studyType":159,"phases":4,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":46},"100493629","bipolar-radio-frequency-ablation-after-standard-unipolar-approach---prospective-registry-100493629","NCT05707637","Bipolar Radio-frequency Ablation After Standard Unipolar Approach - Prospective Registry.","Bipolar Radio-frequency Ablation After Standard Unipolar Approach for Ventricular Arrhythmias Originating From the Base of the Heart. The BiUniVA Prospective Registry","BiUniVA","Inclusion Criteria:\n\n1. Baseline Holter ECG before initial unipolar ablation within 6 months prior to the procedure, performed without antiarrhythmic drugs (beta-blockers allowed).\n2. Initial unipolar ablation of VA originating from the base of the heart (R in II, III and aVF) performed according to the standard scheme which includes detailed measurements of EP parameters at each examined and\u002For ablated site and inspection of all three regions (RVOT with PA, GCV and LVOT\u002FAoCusps\u002FAMC\u002FMA) in cases with unsatisfactory EP parameters or failed ablation at first or second site.\n3. Typical indications for ablation: a. \\> 10 000 PVC in 24-hour Holter ECG or b. \\> 10% PVC in 24-hour Holter ECG or c. less frequent but symptomatic PVC or d. at least 3 episodes symptomatic non-sustained ventricular tachycardia (nsVT) (\\>3 QRS evolutions) in Holter ECG, regardless of the amount of PVC or e. sustained ventricular tachycardia (sVT), regardless of nsVT or PVC\n4. Written informed consent\n\nExclusion Criteria:\n\n1. History of \\> 1 unipolar ablation for VA originating at the base of the heart\n2. Lack of properly acquired EP parameters during baseline unipolar ablation\n3. Lack of baseline Holter ECG performed \\\u003C 6 months prior to initial unipolar ablation\n4. Absence of typical indication for ablation\n5. Lack of written informed consent for participation in the study",{"count":90,"type":20},"1 Month","OBSERVATIONAL","Treatment of ventricular arrhythmias (VA) originating at the base of the heart may be challenging. Unipolar radio-frequency (RF) ablation is a standard approach to treat VA, however, it fails in 10 to 75% of patients, depending on the localization of VA. The main reason for unipolar ablation failure is the intramural location of the source of VA. In such patients, bipolar ablation may occur effective. However, there are no prospective studies or registries on consecutive patients wilt failed unipolar ablation, therefore, the proportion of candidates for bipolar ablation after failed unipolar approach is not known. Also, invasive electrophysiological parameters associated with successful unipolar and bipolar ablation have not been well established. It has been hypothesised that (1) bipolar ablation fails in 12-75% (mean 30%) of consecutive patients and these patients are candidates for bipolar ablation, (2) local ventricular signal precocity \\> 20 ms, unipolar signal without R wave and pace mapping 12\u002F12 predict effective unipolar ablation but not bipolar ablation, (3) morphology of VA from surface ECG can identify patients with possible intramural localization, and (4) successful ablation results in improvement of quality of life (QoL).\n\nAims:\n\n1. To assess how many patients after failed unipolar ablation need redo procedure with bipolar ablation (primary end-point)\n2. To assess which intraprocedural electrophysiological parameters predict success during standard unipolar ablation (secondary endpoint)\n3. To assess short term efficacy of bipolar ablation (secondary endpoint)\n4. To assess one-month efficacy of bipolar ablation (secondary endpoint)\n5. To assess which intraprocedural electrophysiological parameters predict success during redo bipolar ablation (secondary endpoint)\n6. To evaluate the performance of ECG-based algorithms in predicting the localization \u002F origin of VA, especially of transmural origin (secondary endpoint)\n7. To assess the effects of ablation on QoL (secondary endpoint)Methods. The study group consists of all consecutive patients who underwent unipolar ablation of VA originating from the base of the heart in the Grochowski Hospital and collaborating centres. All these patients are referred to Grochowski Hospital for further follow-up and treatment if needed, including bipolar ablation if initial unipolar approach failed. In all patients acute and one-month efficacy of unipolar and bipolar ablation is assessed.",[162],"Ventricular Arrythmia",[142,164,165,166],"unipolar ablation","bipolar ablation","base of the heart",{"date":168,"type":38},"2025-05-13",{"date":170,"type":38},"2022-11-02",{"date":172,"type":20},"2026-02-01",{"name":44,"class":45},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":115,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100548247","early-detection-of-esophageal-squamous-cancer-with-the-capsule-sponge-device-100548247","NCT06418516","Early Detection of Esophageal Squamous Cancer With the Capsule Sponge Device","Early Detection of Esophageal Squamous Cell Carcinoma With the Capsule Sponge Device Coupled With Molecular Biomarkers and Machine Learning","ANGELA","Inclusion Criteria:\n\n1. Patients with esophageal squamous cell cancer (ESCC):\n\n   * Patients ≥18 years of with adequate performance status for endoscopy\n   * Newly diagnosed ESCC suitable for endoscopic or oncological treatment (Rth\u002FChth)\n   * Patients currently undergoing oncological treatment (Rth\u002FChth)\n   * Consent to provide tissue samples for the study\n   * Dysphagia grade ≤2 (able to swallow mixed foods and tablets)\n2. Patients at high risk for ESCC:\n\n   * Patients ≥18 years of age with adequate performance status for endoscopy\n   * Prior definitive treatment for head and neck cancer (cancer of the oral cavity, hypopharyngeal cancer, laryngeal carcinoma) and at least 12 months post-therapy (both Rth, Chth, and combination treatment)\n   * Prior definitive endoscopic treatment for early ESCC in the past (at least 6 months since completion)\n   * Consent to provide tissue samples for the study\n   * Dysphagia grade ≤2\n3. Healthy controls - Patients ≥18 years old undergoing endoscopic evaluation for typical GI symptoms other than dysphagia (e.g., GERD, dyspepsia, etc.) without significant risk factors for ESCC\n\nExclusion Criteria (for all patients):\n\n* Patients currently on anticoagulant treatment (warfarin, acenocoumarol) with no possibility of stopping \u002F modification\n* Dysphagia grade ≥3 (able to swallow only liquid foods)\n* History of myocardial infarction or other cardiovascular event within 6 months of enrolment\n* Neurological diseases associated with impaired swallowing\n* Patients in long-term care or institutional care (physical, psycho-social disorders, intellectual disability).",{"count":183,"type":20},340,[23],"Esophageal squamous cell carcinoma accounts for \\~90% of the nearly half-million annual incident cases of esophageal cancer worldwide. The high costs and invasiveness of upper endoscopy constitute a limitation in providing adequate surveillance for at-risk individuals, including those with previous head and neck cancer. The ANGELA study is a prospective evaluation of the minimally-invasive capsule-sponge device, coupled with tissue biomarkers (p53-immunohistochemistry), to detect squamous neoplasia in high-risk individuals.",[187,188,189],"Esophageal Cancer","Head and Neck Cancer","Squamous Cell Carcinoma",[191,192,187,193],"Prevention","Screening","Capsule Sponge","2024-05-13",{"date":196,"type":38},"2024-05-17",{"date":198,"type":20},"2024-06-01",{"date":200,"type":20},"2027-06-01",{"name":44,"class":45},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":115,"sex":55,"minAge":210,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100474726","infection-prevention-after-tka-with-or-without-vancomycin-100474726","NCT05461651","Infection Prevention After TKA With or Without Vancomycin","Prospective, Randomized, Double Blinded Trial Comparing Clinical, Radiological and Laboratory Outcomes in Prevention of Infection After Total Knee Arthroplasty With or Without Vancomycin.","TKA_Vanco","Inclusion Criteria:\n\n* Gosnartrosis\n\nExclusion Criteria:\n\n* no informed consent to participate in the study age under 40 multilligament injury or single plane knee instability another musculoskeletal disorders in lower limb ASA score \\> II","40 Years",{"count":212,"type":20},1800,[23],"Prospective, Randomized, Double Blinded Trial Comparing Clinical, Radiological and Laboratory Outcomes in prevention of infection after Total Knee Arthroplasty With or Without Vancomycin.",[216],"Infection",[218],"TKA, Vancomycin","2022-07-13",{"date":221,"type":38},"2022-07-18",{"date":223,"type":38},"2021-09-01",{"date":225,"type":20},"2029-01-01",{"name":44,"class":45},""]